How Mixed Q2 Earnings and Higher EPS Guidance Will Impact Elevance Health (ELV) Investors

In July 2026, Elevance Health reported second-quarter results showing revenue of US$50,474 million but lower net income of US$1,463 million compared with the prior year, while also continuing dividends and share repurchases.
Despite the earnings decline, management raised full-year 2026 diluted EPS guidance to at least US$20.10, signaling confidence alongside ongoing capital returns.
Next, we’ll examine how Elevance Health’s higher full-year earnings guidance shapes its investment narrative...